Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Jean-Jacques Kiladjian, Pierre Zachée, Masayuki Hino, Fabrizio Pane, Tamas Masszi, Claire N. Harrison, Ruben A. Mesa, Carole B. Miller, Francesco Passamonti, Simon Durrant, Martin Griesshammer, Keita Kirito, Carles Besses, Beatriz Moiraghi, Elisa Rumi, Vittorio Rosti, Igor W. Blau, Nathalie Francillard, Tuochuan Dong, Monika Wroclawska, Alessandro M. Vannucchi, Srdan Verstovsek
Institutions: Hôpital Saint-Louis, Université Paris Diderot, Ziekenhuisnetwerk Antwerpen Stuivenberg, Osaka City University, Federico II University Hospital, University of Naples Federico II, Semmelweis University, Guy's and St Thomas' NHS Foundation Trust, Mays Cancer Center at UT Health San Antonio, Saint Agnes Hospital, Ospedale di Circolo e Fondazione Macchi, Royal Brisbane and Women's Hospital, Johannes Wesling Klinikum Minden, University of Yamanashi, Universitat Autònoma de Barcelona, Hospital Del Mar, Hospital del Mar Research Institute, Hospital Ramos Mejía, Policlinico San Matteo Fondazione, Charité – Universitätsmedizin Berlin, Novartis (France), Novartis (Switzerland), Azienda Ospedaliero-Universitaria Careggi, University of Florence, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2920145783